<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04912622</url>
  </required_header>
  <id_info>
    <org_study_id>Cellularis Studie 01</org_study_id>
    <secondary_id>EKNZ2020-02454</secondary_id>
    <nct_id>NCT04912622</nct_id>
  </id_info>
  <brief_title>RPE Characterisation With Transscleral Optical Phase Imaging in Retinal Disorders</brief_title>
  <acronym>CEL01LUKS</acronym>
  <official_title>Cross Sectional Study: in Vivo Morphometric Characterisation of Human Retinal Pigment Epithelium With Transscleral Optical Phase Imaging in Photoreceptor/ Retinal Pigment Epithelium/ Bruch's Membrane/ Choriocapillaris Complex Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luzerner Kantonsspital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luzerner Kantonsspital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Accumulating evidence suggest that the functional unit of photoreceptor/ retinal pigment&#xD;
      epithelium (RPE)/Bruch's membrane/choriocapillaris plays a key role in pathophysiologic&#xD;
      processes of a wide range of medical retinal disorders of the eye. Little is known about in&#xD;
      vivo morphometric characteristics of human RPE cells as in vivo observation of these cells&#xD;
      was so far technically challenging and hence nearly impossible to implement in a clinical&#xD;
      setting. Transscleral optical phase imaging is a novel in-vivo microscopy technique allowing&#xD;
      human RPE imaging on a cellular level with the potential of clinical application in a&#xD;
      multimodal retinal imaging approach for diagnostic purpose in medical retina patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 19, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Control group: 110 individuals with healthy retina Patient group: 95 individuals with diseased retina Exclusion: age &lt; 18y, pregnancy, epilepsy, no informed consent</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RPE morphology</measure>
    <time_frame>12 months</time_frame>
    <description>RPE cell density (number of cells per mm^2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>averaged RPE cell area [um2] Averaged number of neighbors of RPE cells [unitless] Averaged RPE spacing [um] Averaged RPE pigmentation parameter [unitless]</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">205</enrollment>
  <condition>Retinal Disease</condition>
  <condition>Eye Disease</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device: Cellularis version 2.0 imaging Image acquisition of retinal pigment epithelium (RPE) cells of central retina with consecutive qualitative and quantitative description of these retinal cell layers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device: Cellularis version 2.0 imaging Image acquisition of retinal pigment epithelium (RPE) cells of central retina with consecutive qualitative and quantitative description of these retinal cell layers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Clinical Trial</intervention_name>
    <description>Retinal image acquisition with Cellularis version 2.0</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed Consent as documented by signature (Appendix Informed Consent Form)&#xD;
&#xD;
          -  Patients with a medical retinal disease involving the retinal pigment epithelium (age&#xD;
             related macular degeneration, diabetic retinopathy, retinal vascular occlusive&#xD;
             disease, central serous chorioretinopathy, tapetoretinal degeneration)&#xD;
&#xD;
          -  Participants with healthy eyes for the control group&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to follow the procedures of the study due to language problems,&#xD;
             psychological disorders, dementia etc. of the participant&#xD;
&#xD;
          -  Aged &lt; 18 years.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Epilepsy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Leila S. Eppenberger, MD, MSc. ETH</last_name>
    <phone>+41 41 205 1323</phone>
    <email>leila.eppenberger@luks.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Schmid, MD, Chief physician</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Lucerne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leila S. Eppenberger, MD, MSc. ETH</last_name>
      <phone>+41 41 205 1323</phone>
      <email>leila.eppenberger@luks.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

